E.K. Geissler et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. 2016 Jan;100(1):116-25.

van Meer S, van Erpecum KJ, Sprengers D, Coenraad MJ, Klümpen HJ, Jansen PL, IJzermans JN, Verheij J, van Nieuwkerk CM, Siersema PD, de Man RA. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9

Levolger S, van Vledder MG, Muslem R, Koek M, Niessen WJ, de Man RA, de Bruin
RW, Ijzermans JN. Sarcopenia impairs survival in patients with potentially
curable hepatocellular carcinoma. J Surg Oncol. 2015 Aug 12.

Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man
RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in
hepatocellular carcinoma in a low-endemic western area. Br J Cancer. 2015 Jun
9;112(12):1911-20.

Buschow SI, Sprengers D, Woltman AM. To target or not to target viral antigens
in HBV related HCC? J Hepatol. 2015 Jun;62(6):1449-50.

Blanc JF, Frulio N, Chiche L, Sempoux C, Annet L, Hubert C, Gouw AS, de Jong
KP, Bioulac-Sage P, Balabaud C. Hepatocellular adenoma management: call for
shared guidelines and multidisciplinary approach. Clin Res Hepatol Gastroenterol.
2015 Apr;39(2):180-7.

van Ginkel WG, Gouw AS, van der Jagt EJ, de Jong KP, Verkade HJ, van Spronsen
FJ. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
Pediatrics. 2015 Mar;135(3):e749-52.

Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C,
Polak WG, Grünhagen D, Pan Q, Janssen H, Garcia-Romo GS, Biermann K, Tjwa ET,
IJzermans JN, Kwekkeboom J, Sprengers D. Tumor-infiltrating plasmacytoid
dendritic cells promote immunosuppression by Tr1 cells in human liver tumors.
Oncoimmunology. 2015 Mar 19;4(6)

van Meer S, de Man RA, van den Berg AP, Houwen RH, Linn FH, van Oijen MG,
Siersema PD, van Erpecum KJ. No increased risk of hepatocellular carcinoma in
cirrhosis due to Wilson disease during long-term follow-up. J Gastroenterol
Hepatol. 2015 Mar;30(3):535-9.

Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott
E, Schütte K, Verslype C, Walecki J, Malfertheiner P; SORAMIC study group. Safety
and toxicity of radioembolization plus Sorafenib in advanced hepatocellular
carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 2015
Feb;35(2):620-6.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ,
Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM,
El-Nowiem S. Linifanib versus Sorafenib in patients with advanced hepatocellular
carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015 Jan
10;33(2):172-9.

Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach
LL, de Man RA, Ijzermans JN, Janssen HL, Stubbs AP, Sprengers D, Bruno MJ,
Metselaar HJ, Ten Hagen TL, Kwekkeboom J, Peppelenbosch MP, Pan Q. SMAD4 exerts a
tumor-promoting role in hepatocellular carcinoma. Oncogene. 2014 Dec 22.

Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP, Pan Q.
Multipotent mesenchymal stromal cells in liver cancer: implications for tumor
biology and therapy. Biochim Biophys Acta. 2014 Dec;1846(2):439-45.

Eskens FA, van Erpecum KJ, de Jong KP, van Delden OM, Klumpen HJ, Verhoef C,
Jansen PL, van den Bosch MA, Méndez Romero A, Verheij J, Bloemena E, de Man RA.
Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and
therapy. Neth J Med. 2014 Jul;72(6):299-304.

Burgmans MC, van Erkel AR, Too CW, Coenraad M, Lo RH, Tan BS. Pilot study
evaluating catheter-directed contrast-enhanced ultrasound compared to
catheter-directed computed tomography arteriography as adjuncts to digital
subtraction angiography to guide transarterial chemoembolization. Clin Radiol.
2014 Oct;69(10):1056-61.

Zeng W, van den Berg A, Huitema S, Gouw AS, Molema G, de Jong KP. Correlation
of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2
expression and angiogenic factors in cirrhotic and noncirrhotic human
hepatocellular carcinoma. PLoS One. 2014 Apr 23;9(4):

Bieze M, Klümpen HJ, Verheij J, Beuers U, Phoa SS, van Gulik TM, Bennink RJ.
Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed
tomography for intra- and extrahepatic hepatocellular carcinoma. Hepatology. 2014
Mar;59(3):996-1006.

van Meer S, van Erpecum KJ, Schrier GH, Verhoef C, Verheij J, de Man RA, van
der Geest LG. [Diagnostics and treatment of hepatocellular carcinoma: trends in
the Netherlands in the period 2003-2011]. Ned Tijdschr Geneeskd. 2014;158:A7074.
Dutch. PubMed PMID: 24594129.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C,
Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase I study
investigating everolimus combined with sorafenib in patients with advanced
hepatocellular carcinoma. J Hepatol. 2013 Dec;59(6):1271-7.

van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for
hepatocellular carcinoma in chronic liver disease: evidence and controversies.
World J Gastroenterol. 2013 Oct 28;19(40):6744-56.

Witjes CD, ten Kate FJ, Verhoef C, de Man RA, IJzermans JN.
Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic
livers. J Clin Pathol. 2013 Aug;66(8):687-91.

Post-radioembolization yttrium-90 PET/CT – part 1: diagnostic reporting. Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, Takano A, Burgmans MC, Irani FG, Teo TK, Yeow TN, Gogna A, Lo RH, Tay KH, Tan BS, Chow PK, Satchithanantham S, Tan AE, Ng DC, Goh AS. EJNMMI Res. 2013 Jul 25;3(1):56.

Post-radioembolization yttrium-90 PET/CT – part 2: dose response and tumor predictive dosimetry for resin microspheres. Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, Budgeon C, Boucek JA, Francis RJ, Cheo TS, Burgmans MC, Irani FG, Lo RH, Tay KH, Tan BS, Chow PK, Satchithanantham S, Tan AE, Ng DC, Goh AS. EJNMMI Res. 2013 Jul 25;3(1):57.

Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C,
Ijzermans JN. Recently introduced biomarkers for screening of hepatocellular
carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013
Mar;7(1):59-64.

Hoekstra LT, Bieze M, Busch OR, Gouma DJ, van Gulik TM. Staging laparoscopy
in patients with hepatocellular carcinoma: is it useful? Surg Endosc. 2013
Mar;27(3):826-31.

Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J,
Verheij J, Janssen HL, Sprengers D. Activated tumor-infiltrating CD4+ regulatory
T cells restrain antitumor immunity in patients with primary or metastatic liver
cancer. Hepatology. 2013 Jan;57(1):183-94.

Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of DSA and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization? MC Burgmans, CW Too, YH Kao, ASW Goh, PKH Chow, BS Tan, KH Tay, RHG Lo Eur J Radiol. 2012 Dec;81(12):3979-84

Witjes CD, Verhoef C, Kwekkeboom DJ, Dwarkasing RS, de Man RA, Ijzermans JN.
Is bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma
patients? J Surg Res. 2013 May;181(2):256-61.

Radioembolization after portal vein embolization in a patient with multifocal hepatocellular carcinoma. Burgmans MC, Irani FG, Chan W, Teo T, Kao YH, Goh ASW, Chow PKH, Lo HG. Cardiovasc Intervent Radiol. 2012 Dec;35(6):1519-23

Witjes CD, Willemssen FE, Verheij J, van der Veer SJ, Hansen BE, Verhoef C,
de Man RA, Ijzermans JN. Histological differentiation grade and microvascular
invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI.
J Magn Reson Imaging. 2012 Sep;36(3):641-7.

Radioembolization with infusion of Y-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe. Burgmans MC, Kao YH, Irani FG, Dames E, Teo TK, Goh ASW, Chow PKH, Tay KH, Lo RHG. J Vasc Interv Radiol. 2012 Oct;23(10):1294-301

Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of
miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012
Jun;56(6):1371-83.

Witjes CD, Polak WG, Verhoef C, Eskens FA, Dwarkasing RS, Verheij J, de Man
RA, Ijzermans JN. Increased alpha-fetoprotein serum level is predictive for
survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers. Dig
Surg. 2012;29(6):522-8.

Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, Ijzermans
JN, de Man RA, Coebergh JW, Verhoef C. Hepatocellular carcinoma in a low-endemic
area: rising incidence and improved survival. Eur J Gastroenterol Hepatol. 2012
Apr;24(4):450-7.

Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective Yttrium-90 radioembolization. Yung Hsiang Kao, Andrew Eik Hock Tan, Mark Christiaan Burgmans, Farah Gillan Irani, Li Ser Khoo, Richard Hoau Gong Lo, Kiang Hiong Tay, Bien Soo Tan, Pierce Kah Hoe Chow, David Chee Eng Ng, Anthony Soon Whatt Goh. J Nucl Med. 2012 Apr;53(4):559-66

Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of
hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011
Jan;26(1):28-35.

Zeng W, Gouw AS, van den Heuvel MC, Molema G, Poppema S, van der Jagt EJ, de
Jong KP. Hepatocellular carcinomas in cirrhotic and noncirrhotic human livers
share angiogenic characteristics. Ann Surg Oncol. 2010 Jun;17(6):1564-71.